Pre-made Derlotuximab benchmark antibody ( Whole mAb Radiolabelled, anti-DNA;H1 Complex therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-143

Pre-made Derlotuximab benchmark antibody (Whole mAb Radiolabelled, anti-DNA;H1 Complex therapeutic antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Iodine (131 I) derlotuximab biotin is a monoclonal antibody designed for the treatment of recurrent glioblastoma multiforme. This drug was developed by Peregrine Pharmaceuticals, Inc.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-143-1mg 1mg Inquiry
GMP-Bios-ab-143-10mg 10mg Inquiry
GMP-Bios-ab-143-100mg 100mg Inquiry
GMP-Bios-ab-143-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Pre-Made Derlotuximab biosimilar, Whole mAb Radiolabelled: Anti-DNA/H1 Complex therapeutic antibody
INN Name Derlotuximab
TargetDNA;H1 Complex
FormatWhole mAb Radiolabelled
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2015
Year Recommended2016
CompaniesAvid Bioservices;MediPharm Biotech
Conditions ApprovedLung cancer
Conditions ActiveGlioblastoma
Conditions Discontinuedna
Development Techna